HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2007.101014v1 54/6/1060    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karon, B. S. Articles by Jaffe, A. S. Search for Related Content PubMed PubMed Citation Articles by Karon, B. S. Articles by Jaffe, A. S. Related Collections Hemostasis and Thrombosis

Aspirin Responsiveness in Healthy Volunteers Measured with Multiple Assay Platforms

¹ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

^aAddress correspondence to this author at: Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St. SW, Rochester, MN 55905. Fax: 507-538-7060; e-mail karon.bradley{at}mayo.edu.

Background: We evaluated the sensitivity, precision, and concordance of 4 assays designed to detect aspirin responsiveness or resistance.

Methods: Twenty-nine healthy laboratory volunteers took 80 mg aspirin for 7 days, and a subset of volunteers took 325 mg aspirin for an additional 7 days. We measured platelet function by light transmission aggregometry with arachidonic acid, PFA-100, and VerifyNow. PFA-100 and VerifyNow assays were performed in duplicate to assess method imprecision. Some volunteers had samples taken within 2–4 h of the final dose of aspirin and again within 20–24 h of the final dose. We measured urinary 11-dehydro-thromboxane B₂ at baseline and after 80 or 325 mg aspirin.

Results: No volunteers were nonresponsive to aspirin therapy as measured by the PFA-100. One of 29 participants demonstrated lack of response to aspirin as measured by VerifyNow and urinary 11-dehydro-thromboxane B₂; 2 of 29 demonstrated lack of response as measured by light transmission aggregometry. Imprecision was <10% for the PFA-100 and VerifyNow. Concordance was high (>90%) between all assays. Neither aspirin dose (80 vs 325 mg) nor timing between final dose of aspirin and blood draw (2–4 vs 20–24 h) affected any of the assays.

Conclusions: Light transmission aggregometry, PFA-100, VerifyNow, and urinary 11-dehydro-thromboxane B₂ are all sensitive to the effects of aspirin in healthy individuals. Variables such as aspirin dose, timing between final dose of aspirin and blood collection, and imprecision do not affect the ability of the assays to detect aspirin effect on platelet function.

The following articles in journals at HighWire Press have cited this article:

				A. M. Naidech, B. Jovanovic, S. Liebling, R. K. Garg, S. L. Bassin, B. R. Bendok, R. A. Bernstein, M. J. Alberts, and H. H. Batjer Reduced Platelet Activity Is Associated With Early Clot Growth and Worse 3-Month Outcome After Intracerebral Hemorrhage Stroke, July 1, 2009; 40(7): 2398 - 2401. [Abstract] [Full Text] [PDF]

eLetters: